Clinical trials: Adenocarcinoma of the Prostate
Prostate Adenocarcinoma
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing…
- Trial name
- NCT03762759
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University
Prostate Cancer
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Hormone therapy combined with radiation therapy may be a more effective treatment for prostate cancer.
- Trial name
- NCT00769548
- Testing
- flutamide, goserelin acetate, low-LET photon therapy
- Volunteers
- 1,322 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Prostate Adenocarcinoma, PSA Level Greater Than 0.2
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back.
- Conditions
- Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression
- Trial name
- NCT03501940
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Andrei Iagaru
Cancer Survivor, Obesity
Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer
This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors.
- Conditions
- Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma
- Trial name
- NCT03880422
- Testing
- Dietary Intervention, Educational Intervention, Exercise Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005048
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- NYU Langone Health
Advanced Solid Tumors, Adenocarcinoma of the Prostate
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were…
- Trial name
- NCT01094288
- Testing
- Alisertib, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Adenocarcinoma, PSA Progression
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come…
- Conditions
- Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT03698370
- Testing
- Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Andrei Iagaru
Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
This phase II trial studies how well docetaxel or abiraterone acetate work when combined with androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread to other parts of the…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer
- Trial name
- ACADEMIC (NCT03827473)
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Prostate Cancer, Prostate Adenocarcinoma
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- OCEAN (NCT06392295)
- Testing
- Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Miami
Prostate Cancer
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00020254
- Testing
- aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Prostate Adenocarcinoma
MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer
The hypotheses of this study are: 1. Delivery of single fraction Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) to the dominant tumor lesion(s) in the prostate as identified by multiparametric functional Magnetic…
- Trial name
- LEAD (NCT01411319)
- Testing
- Lattice Extreme Ablative Dose Radiation Therapy, Standard IMRT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Prostate Adenocarcinoma
Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device as a neo-adjuvant therapy in men with prostate cancer
- Trial name
- NCT04543903
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 3 sites in Israel
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
As there is no prospective data on the combination of abiraterone and salvage radiotherapy, the aim of this study is to further evaluate the safety profile of abiraterone acetate plus prednisone in patients with prostate cancer…
- Trial name
- CARLHA (NCT01780220)
- Testing
- Abiraterone
- Where
- 5 sites in France
- Volunteers
- 47 people
- Sponsor
- UNICANCER
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies the side effects and how well abiraterone acetate, prednisone, and apalutamide work with or without ipilimumab or cabazitaxel and carboplatin in treating patients with castration-resistant…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT02703623
- Testing
- Abiraterone Acetate, Apalutamide, Cabazitaxel
- Where
- 3 sites in United States
- Volunteers
- 196 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent…
- Trial name
- NCT02692105
- Testing
- Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Prostate Cancer
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide and bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00244920
- Testing
- bicalutamide, leuprolide acetate, squalamine lactate
- Sponsor
- OHSU Knight Cancer Institute